AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Intermittent Erector Spinae Plane Block Via Subcutaneous Port for Cancer Pain

RecruitingNAAges 18 Years - anyAllHanoi Medical University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Cancer-related pain is a common and challenging problem in patients with lung cancer, often requiring long-term pain management. Conventional pain treatments, including systemic medications, may not provide adequate relief or may cause significant side effects. The erector spinae plane (ESP) block is a regional anesthesia technique that can help reduce pain by delivering local anesthetic near the nerves supplying the chest wall. This study aims to evaluate the effectiveness and safety of intermittent ESP block administered through a subcutaneous port for controlling cancer-related pain in patients with lung cancer. Eligible patients with lung cancer and moderate to severe pain will receive intermittent ESP block injections via a subcutaneous port as part of their pain management plan. Pain intensity, analgesic requirements, and potential side effects will be assessed over time. The re

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria * Adult patients diagnosed with advanced-stage lung cancer who are currently receiving palliative care only. * Presence of chronic cancer-related chest pain lasting longer than 1 month, localized to the thoracic region due to chest wall invasion, pleural involvement, or bone metastases. * Performance status โ‰ค 3 according to the Eastern Cooperative Oncology Group (ECOG), allowing placement of a subcutaneous port and maintenance of local anesthetic administration. * Inadequate pain control with conventional analgesic therapies or clinical indication for the addition of regional analgesia. * Ability to understand the study procedures and provide written informed consent after receiving a full explanation of the intervention. Exclusion Criteria: * Chest pain with radiation to the upper extremities, neck, or shoulder, suggestive of non-localized thoracic pain. * Severe hepatic or renal dysfunction, or severe heart failure (New York Heart Association class III-IV). * Local infection at the injection or port placement site, or uncontrolled systemic infection. * Severe cachexia or insufficient subcutaneous tissue that does not allow safe coverage of the subcutaneous port. * Known allergy to amide-type local anesthetics or other contraindications to regional anesthesia. * Severe cognitive impairment, altered consciousness, or inability to cooperate with post-intervention monitoring. * Lack of adequate caregiver support for home-based follow-up after discharge or inability to coordinate follow-up with local healthcare facilities. * Severe coagulation disorders, defined as: * International normalized ratio (INR) \> 1.5 * Activated partial thromboplastin time (aPTT) \> 40 seconds * Fibrinogen \< 1.5 g/L * Platelet count \< 50 ร— 10โน/L.
๐Ÿ’Š

What it tests

  • Erector Spinae Plane Block
๐Ÿ“

Where

1 site
Hanoi Medical University
Hanoi, Vietnam
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy